Scholar Rock resubmits apitegromab MAA to EMA for SMA
Scholar Rock (SRRK) has resubmitted its apitegromab marketing authorisation application (MAA) to the European Medicines Agency (EMA) for treatment of children and adults with spinal muscular atrophy (SMA).
Story updates
12:09:56 PM UTC
SquawkNews
SRRK - Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)